Clinical Trial Update: Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of low-dose cyclophosphamide with outpatient IV interleukin-2 in metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Proleukin (aldesleukin)

Snippet

Sponsor: Western Regional Medical Center | Conditions: Metastatic Melanoma | Phase 2 | Status: WITHDRAWN